Skip to main content

Table 2 Drug-related toxicity per patient for colorectal cancer patients treated with FOLFIRI® and bevacizumab in first-line treatment (n = 62)

From: FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

 

NCI-CTCAE* Grade 1–2

NCI-CTCAE Grade 3–4

 

N

(%)

N

(%)

Neutropenia

11

(17.7)

10

(16.1)

Febrile neutropenia

0

0

Anemia

4

(6.5)

0

Thrombocytopenia

1

(1.6)

0

Nausea

20

(32.3)

1

(1.6)

Vomiting

6

(9.7)

0

Diarrhea

19

(30.6)

7

(11.3)

Stomatitis/mucositis

16

(25.8)

2

(3.2)

Neurosensory

1

(1.6)

1

(1.6)

Asthenia

3

(4.8)

4

(6.4)

Gastrointestinal perforation

0

0

Hypertension

1

(1.6)

0

Venous thromboembolism

3

(4.8)

0

Proteinuria

8

(12.9)

0

Bleeding

7

(11.3)

0

Alopecia

10

(16.1)

0

  1. *NCI-CTCAE - National Cancer Institute Common Terminology Criteria for Adverse Events v3.0.